NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Electronic Arts Inc. (NASDAQ: EA)’s sale to an investor consortium comprised of PIF, Silver Lake, and Affinity Partners for $210.00 per share in cash. If you are an Electronic Arts shareholder, click here to learn more about your rights and options. Merus N.V ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Merus N.V. (NASDAQ: MRUS) related to its sale to GEnmad A/S. Under the terms of the propose ...

Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline. The acquisition, which has received unanimous support from both companies' boards of directors, is expected to advance Genmab's transition to a fully owned business model. A subsidiary of Genmab will initiate a tender offer to acquire 100% of the common shares of Merus, with the deal projected to close early in the firs ...

此次要约收购中支付的每股普通股 97.00 美元的收购价格较 Merus 2025 年 9 月 26 日的收盘价 68.89 美 元溢价约 41%，较 Merus 30 天成交量加权平均价 67.42 美元溢价约 44%。 来源：市场资讯 （来源：求实药社） 当地时间 9 月 29 日，Genmab A/S 和 Merus NV 今日宣布，双方已达成交易协议。根据协议，Genmab 拟以每股 97.00 美元的价格全现金收购 Merus 的全部股份。此次收购将以现金方式进行，交易价值约为 80 亿美元。 该交易已获得两家公司董事会的一致批准。Genmab 的全资子公司将对 Merus 100% 的普通股发起要约 收购，预计将于 2026 年第一季度初完成。 | 0 = 00 | CARD STORE FOR CONSULTION CONSULTION CONSULTION OF CONSULTION OF | | --- | --- | | [ Global M Genmab | Nealthcare Professionals Patterco & Care Partnerships Contact AND ...

点击蓝字，关注我们 今日上午港股 1. 中国中冶(01618)涨近7%， 机构称矿产资源丰富的建筑企业价值亟待重估。 2. 荣昌生物(09995)再涨超5%， 眼科创新药RC28申报上市，此前已与参天中国达成合作。 3. 来凯医药-B(02105)再涨近6%， 近三个交易日累计涨36%，LAE102 I期临床MAD研究初步结果积极。 4. 优必选(09880)涨超5%， 招商证券国际发表报告指，人形机器人链整机首推优必选，该行上调优必选 目标价。 9. 五矿资源(01208)涨超2%， 拟发行5亿美元于2030年到期的零息可换股债券，用于境外债务再融资。 10. 中国中车(01766)涨超1%， 9月29日，中国中车发布公告，公司及下属企业近三个月合计签订约543.4 亿重大合同。 昨日 美股 1. 阿里巴巴(BABA.US)涨4.65%， 摩根士丹利发表布研报，重申对阿里巴巴"增持"评级，ADR目标价由1 65美元上调至200美元。 2. 理想汽车(LI.US)涨3.57%， 9月27日，理想i6正式于常州智能制造基地开启交付。里昂发研报指，i6车 款销售表现料优于i8。 3. 京东(JD.US)涨0.15 ...

收购交易概述 - 公司以每股97美元现金收购Merus N V 交易总额约80亿美元[1][6] - 交易预计于2026年第一季度初完成 将显著增强公司肿瘤治疗产品组合[1][3] 战略价值与业务影响 - 获得Merus三期临床阶段资产petosemtamab 加速公司向全所有权模式转型[3][6] - 收购后公司将拥有四个专有项目 推动多款新药上市并多元化收入来源[4] - 交易支持公司持续增长至未来十年 强化其在制药行业地位[3][4] 市场反应与股价表现 - Merus股价在公告后上涨38% 显示市场对交易持积极态度[5] - Leerink Partners给予公司34美元目标价 较当前29.33美元存在16.61%上行空间[2][6] - 公司股票当日交易区间28.36-29.34美元 年内波动区间17.24-29.52美元[2][5] 公司基本面 - 当前市值约185.1亿美元 纳斯达克日成交量503万股[4] - 股价近期微涨0.89% 单日变动0.26美元[2]

公司核心业务 - 专注于开发创新癌症疗法 特别是双特异性抗体技术[1] - 主要竞争对手为Genmab A/S 目前正与该公司进行重大交易[1] 股价表现与估值 - 当前股价94.12美元 过去一年大幅上涨36.62%[3] - 股价区间在过去一年介于33.19美元至94.55美元之间[4] - 公司市值约71.2亿美元 显示其在生物技术领域的重要地位[4] - 今日交易量达1486万股 显示投资者兴趣浓厚[5] 并购交易进展 - Genmab A/S同意以每股97美元价格收购公司[2] - Wells Fargo设定97美元目标价 较当前股价存在2.69%上涨空间[2] - 当前股价94.46美元 接近收购报价水平[2] 交易合规性审查 - Halper Sadeh LLC正在调查97美元收购价对股东是否公平[3] - 调查重点在于公司董事会是否尽到对股东的受托责任[3] - 利益相关方密切关注以确保收购价格反映公司真实价值[5]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday.Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session.Shares of cannabis-linked stocks traded higher after President Donald Trump posted a video on Truth Social on Sunday, promoting the potential health benefits of cannabis. Cannabis stocks lit up on Monday after Trump resurrected hopes for a change in federal drug policy.Tilray Brands shares jumped 39.2% to $1.5983 on Monday.Here are some ot ...

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion. The transaction is anticipated to close by early in the first quarter of 2026. The proposed acquisition of Merus is expected to accelerate Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained gro ...